论文部分内容阅读
目的：研究大剂量顺铂（ＤＤＰ）化疗的肾毒性及监测方法。方法：对１３例骨肉瘤术后病人，按每平方米体表面积１００ｍｇＤＤＰ静脉大剂量化疗。化疗前及化疗后９６ｈ分别测定血清尿素（ＵＲＥＡ）、血清肌酐（Ｃｒ）、血和尿中β＿２－微球蛋白（β＿２－Ｍ）的含量。结果：化疗后有１０例病人尿中β＿２－Ｍ含量升高（Ｐ＜０．０５）。结论：根据尿中β＿２－Ｍ值来观察接受大剂量顺铂化疗的骨肉瘤病人肾小管的损害程度，结果稳定可靠。化疗前尿中β＿２－Ｍ超过０．２５ｕｇ／Ｌ以上者要停止大剂量顺铂的化疗。
Objective: To study the nephrotoxicity and monitoring methods of high-dose cisplatin (DDP) chemotherapy. Methods: Thirteen patients with postoperative osteosarcoma received high-dose intravenous chemotherapy at 100 mg DDP per square meter of body surface area. The levels of serum urea (UREA), serum creatinine (Cr), blood and urinary β2-microglobulin (β 2 -M) were determined before and 96 hours after chemotherapy. Results: The urinary β2-M content was increased in 10 patients after chemotherapy (P<0.05). Conclusion: According to the urinary β 2 -M value, the degree of tubular damage in osteosarcoma patients receiving high-dose cisplatin chemotherapy was observed. The results were stable and reliable. Chemotherapy with high doses of cisplatin should be stopped when the urinary β 2 -M exceeds 0.25 μg/L.